Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0NLEYN
ADC Name	Tra-IR700
Synonyms	Trastuzumab-IR700 Click to Show/Hide
Organization	Rakuten Medical, Inc.
Drug Status	Clinical candidate
Indication	In total 2 Indication(s) Head and neck cancer [ICD11:2B60-2B6E] Clinical candidate Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	IRDye 700DX		Payload Info
Linker Name	Undisclosed
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Sarotalocan

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 54.5	%	MDA-MB-468GFP cells	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 81.8	%	MDA-MB-468GFP cells	Breast adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.50% (Day 7)	Negative HER2 expression (HER2 -)
Method Description	Tra-IR700 (3.6 ug/g) or T-DM1-IR700 (3.6 ug/g) was administered intravenously to mice on Day 1 (with NIR light 6 days after tumor cell transplantation). The dose similar to that of T-DM1 administered to humans (3.6 mg/kg). The NIR-light was irradiated at 1 and 2 days after the drug administration.
In Vivo Model	MDA-MB-468GFP CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468GFP cells		CVCL_DH83
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.80% (Day 7)	Negative HER2 expression (HER2 -)
Method Description	Tra-IR700 (3.6 ug/g) or T-DM1-IR700 (3.6 ug/g) was administered intravenously to mice on Day 1 (with NIR light 6 days after tumor cell transplantation). The dose similar to that of T-DM1 administered to humans (3.6 mg/kg). The NIR-light was irradiated at 1 and 2 days after the drug administration.
In Vivo Model	MDA-MB-468GFP CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468GFP cells		CVCL_DH83

References

Ref 1	Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect. Bioeng Transl Med. 2022 Aug 21;7(3):e10388. doi: 10.1002/btm2.10388. eCollection 2022 Sep.